Top Markets
#1 EXOD EXOD +22.08%
#2 Status Status +13.35%
#3 aelf aelf +9.22%
#4 Gas Gas +5.60%
#5 Tornado Cash Tornado Cash +5.29%
#6 BCGame Coin BCGame Coin +4.98%
#7 B3 (Base) B3 (Base) +4.39%
#8 Fake World Assets Fake World Assets +4.11%
#9 The Black Bull The Black Bull +3.94%
#10 aPriori aPriori +3.79%
Coin of the day
EXOD EXOD
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
LianBio LianBio

LianBio

LIAN
Rankning i aktier #25845
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Aktiekurs
$0.42275
Senast synkroniserad: 2025-07-14
Marknadsvärde
$45.81M
Förändring (1 dag)
-0.89%
Förändring (1 år)
0.00%
Land
US
Handel LianBio (LIAN)

Kategori

Healthcare
Vinst för LianBio (LIAN)
Vinst i 2026 TTM: 0
Enligt de senaste finansiella rapporterna från LianBio är företagets nuvarande vinst 0. År 2026 hade företaget en vinst på 0, lika med vinsten år 2026 som var 0. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för LianBio från 2026 till 2026
Vinst vid slutet av varje år
År Vinst Ändra
Inte tillräckligt med data för de angivna datumen.
Vinst för liknande företag eller konkurrenter
Företag Vinst Skillnad i vinst Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US